Fusion gene: Difference between revisions

Oncogenic fusion genes may lead to a gene product with a new or different function from the two fusion partners. Alternatively, a proto-oncogene is fused to a strong [[Promoter (genetics)|promoter]], and thereby the oncogenic function is set to function by an [[Downregulation and upregulation|upregulation]] caused by the strong promoter of the upstream fusion partner. The latter is common in [[lymphoma]]s, where oncogenes are juxtaposed to the promoters of the [[immunoglobulin]] genes.<ref>{{cite journal | vauthors = Vega F, Medeiros LJ | title = Chromosomal translocations involved in non-Hodgkin lymphomas | journal = Archives of Pathology & Laboratory Medicine | volume = 127 | issue = 9 | pages = 1148–60 | date = September 2003 | pmid = 12946230 | doi = 10.5858/2003-127-1148-CTIINL }}</ref> Oncogenic [[fusion transcript]]s may also be caused by [[trans-splicing]] or [[Conjoined gene|read-through]] events.<ref>{{cite journal | vauthors = Nacu S, Yuan W, Kan Z, Bhatt D, Rivers CS, Stinson J, Peters BA, Modrusan Z, Jung K, Seshagiri S, Wu TD | display-authors = 6 | title = Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples | journal = BMC Medical Genomics | volume = 4 | issue = 1 | pages = 11 | date = January 2011 | pmid = 21261984 | pmc = 3041646 | doi = 10.1186/1755-8794-4-11 }}</ref>

 

 

==Diagnostics==